Venrock Sells Over 5 Million KalVista Shares, Cashing In on a 22.6% Rally Amid Uncertain Earnings Outlook

Venrock’s Recent Sell‑Off Signals a Shift in Position

Venrock Healthcare Capital Partners III, L.P. (VHCP3) has moved a substantial block of KalVista shares—over 5 million—into the market over the last three days, selling between $16.95 and $19.12 per share. The cumulative proceeds total roughly $95 million, leaving VHCP3 with 5,089,354 shares, a 1.2 % stake in the company. The sales were executed at prices that track the stock’s recent 52‑week high of $19.25, suggesting that VHCP3 is capitalizing on the rally that has driven KalVista’s stock up 22.6 % this month and 67.5 % year‑to‑date.

What This Means for Investors and KalVista’s Future

The timing and scale of the sell‑offs raise questions about the health of the company’s valuation. KalVista’s first quarterly earnings, while upbeat on product launch momentum, still reported a loss per share that beat analyst expectations, and the company’s cash runway remains a concern. For shareholders, VHCP3’s divestiture could be interpreted as a rebalancing move rather than a loss of confidence, but the near‑peak pricing suggests a willingness to lock in gains before a potential pullback. If the stock recedes below its 52‑week low of $9.24, the sale proceeds could provide a cushion for the company’s R&D pipeline, yet a sustained decline could erode investor sentiment and pressure management to accelerate commercial traction.

Venrock’s Historical Behaviour in KalVista

Examining VHCP3’s transaction history reveals a pattern of periodic liquidity events: large block sales in March 2026 followed by smaller, more frequent trades in earlier periods. In 2025, VHCP3 sold portions of its holding at prices ranging from $13.42 to $15.57 per share, often after a sharp uptick in the share price. This “sell‑after‑up” strategy is consistent with a fund‑manager approach that seeks to capture upside while maintaining a long‑term equity position. The most recent tranche—over 5 million shares—was executed at a premium relative to the current market price of $18.95, implying a bullish outlook that has yet to materialise in sustained earnings growth.

Key Takeaway for Market Participants

For analysts and shareholders, VHCP3’s recent divestiture signals a potential inflection point. The fund’s exit of a sizable block could depress short‑term liquidity if a broader market correction occurs, while also freeing capital that could be reinvested in other high‑growth biotech opportunities. Investors should watch for any accompanying changes in KalVista’s guidance, as a reduction in institutional ownership often precedes a reassessment of valuation multiples and could prompt a re‑pricing of the stock. In the near term, the company’s ability to convert its commercial momentum into profitability will be the litmus test for whether VHCP3’s exit is a temporary repositioning or a harbinger of more substantial shareholder realignment.